

## UNICARBAZAN

**For the use of a Registered Medical Practitioner or Hospital or a Laboratory only.**  
Abbreviated Prescribing information for UNICARBAZAN (Diethylcarbamazine Citrate with Chlorpheniramine Maleate Tablets)

[Please refer the complete prescribing information available at [www.torrentpharma.com](http://www.torrentpharma.com)]

### PHARMACOLOGICAL PROPERTIES:

#### Mechanism of action

Diethylcarbamazine citrate is a synthetic piperazine derivative with an antihelmintic action. Diethylcarbamazine citrate can be best described as a potent anti-microfilaraemic agent with variable macrofilaricidal properties. The drug is known to exert its effect directly on the parasite and also achieve parasite killing by activating the host immune response. Chlorpheniramine maleate is a potent antihistamine (H1-antagonist). Antihistamines diminish or abolish the actions of histamine in the body by competitive reversible blockade of histamine H1-receptor sites on tissues. Chlorpheniramine maleate also has anticholinergic activity.

### DOSAGE AND ADMINISTRATION:

1 to 2 Tablets 2 to 4 times a day or as directed by the Physician.

**CONTRAINDICATION:** Known hypersensitivity to active ingredients or to any of the excipients; contraindicated for patients who have been treated with MAOIs within the last fourteen days; Serious ocular damage may occur if patient is having co-infection with onchocerciasis.

**WARNINGS & PRECAUTIONS:** UNICARBAZAN must be used with care in patients who have a history of convulsions or who show factors that predispose them to convulsions, should be used with caution in epilepsy; raised intra-ocular pressure including glaucoma; prostatic; hypertrophy; severe hypertension or cardiovascular disease; bronchitis, bronchiectasis or asthma; hepatic impairment; should be avoided in the frail, elderly and debilitated, especially those with cardiac or renal disease and in children under the age of 2 years; special care should be taken or use should be avoided in case of underlying filarial infestation: 1. Lymphatic filariasis - should be managed according to the relevant local or international treatment guidelines; 2. Loa loa - Serious central nervous system problems such as encephalopathy and coma have been observed in patients with Loa loa infections that have been treated with diethylcarbamazine citrate, in particular; 3. Onchocerciasis- must not be administered in patients co-infected with onchocerciasis.

**DRUG INTERACTION:** It can interact with hypnotics or anxiolytics and may cause an increase in sedative effects; it inhibits phenytoin metabolism and can lead to phenytoin toxicity; the anticholinergic effects of Chlorpheniramine maleate are intensified by MAOIs.

**ADVERSE REACTIONS:** Lymphadenitis, lymphangitis, lymph node abscess, lymph node pain, lymphedema, Nausea, vomiting, abdominal pain, diarrhoea, Pyrexia, chills, weakness, malaise, Decreased appetite, Myalgia, arthralgia, chest pain, Dizziness, headache, lethargy, Haematuria, Epididymitis, spermatic cord inflammation, hydrocele, scrotal mass, Dyspnoea, cough, Pruritus, papular rash, Circulatory collapse, orthostatic hypotension, Tachycardia, Optic neuritis, punctate keratitis, iridocyclitis, conjunctivitis, visual field defect, eye pain, lacrimation, photophobia, corneal oedema, Mazotti reaction, Meningoencephalitis helminthic Increased intraocular pressure, Coma, allergic encephalitis, encephalopathy, vertigo, convulsion, Proteinuria

**MARKETED BY:**

**TORRENT PHARMACEUTICALS LTD.**

Torrent House, Off Ashram Road,

Ahmedabad-380 009, INDIA

**IN/UNICARBAZAN 50, 1.25 mg/JUN-19/01/PI**

(Additional information is available on request)